Laboratory Impact of Daratumumab Interference

Starts

November 3, 2026

Ends

November 3, 2026

Format

Online

Location

VIRTUAL

About This Event

Daratumumab, an anti-CD38 monoclonal antibody used to treat multiple myeloma, can interfere with pretransfusion testing by causing panreactivity in indirect antiglobulin tests (IAT) and masking clinically significant antibodies. Standard mitigation using dithiothreitol (DTT)-treated RBCs is labor-intensive and may destroy important antigens (e.g., Kell), potentially delaying urgent testing. In this webinar, Molly Rutherford will discuss the impact of daratumumab on laboratory workflow and blood provision, review current mitigation strategies, and present the evaluation results of a new reagent, DaraClear.